Navigation Links
HeartWare International, Inc. Announces Public Offering of Common Stock
Date:3/11/2013

FRAMINGHAM, Mass. and SYDNEY, March 11, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, 1,500,000 shares of common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC").  HeartWare also intends to grant the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any.

HeartWare intends to use the net proceeds from the offering for working capital and general corporate purposes, including, but not limited to, research and development, expansion of manufacturing capabilities, selling and marketing activities, capital investments in information systems, facilities and infrastructure, and general and administrative support functions to support growth and the acquisition or licensing of or investment in complementary products, technologies or businesses.

J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering.

The offering does not require the prior approval of HeartWare's stockholders under the requirements of the Australian Stock Exchange.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. The offering of securities will be made only by means of a prospectus and the related prospectus supplement. Before you invest, you should read the prospectus and the related prospectus supplement and any other document HeartWare has filed with the SEC for more complete information about HeartWare and the offering. You may get these documents for free by visiting EDGAR on the SEC Website at www.sec.gov. Alternatively, copies of the prospectus and the related prospectus supplement can be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by calling 1-866-803-9204.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.

Forward-Looking Statements
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the commercial launch of the HeartWare® Ventricular Assist System in the U.S., continued support from international customers, progress of clinical trials and post-approval studies, regulatory status, research and development activities, commercialization strategies and the use of proceeds from this offering.  Management believes that these forward-looking statements are reasonable as and when made.  However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.  HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.  We may update our risk factors from time to time in Part II, Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
2. HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
3. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
4. HeartWare Schedules Fourth Quarter Conference Call and Webcast
5. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
6. HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
7. HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be Webcast
8. HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare Conference To Be Webcast
9. HeartWare Reports Third Quarter 2012 Results
10. HeartWare Schedules Third Quarter Conference Call And Webcast
11. HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Taiwan , March 28, 2017  Medeon ... medical device company, is pleased to announce that ... A investment of Panther Orthopedics, Inc., a ... innovative dynamic fixation solutions for orthopedic extremity applications.  ... continues to expand rapidly, primarily due to procedure ...
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, a ... a class action lawsuit on behalf of purchasers of ... ) pursuant and/or traceable to Kitov,s initial public offering ... on the open market from November 20, 2015 through ... The lawsuit seeks to recover damages for Kitov investors ...
(Date:3/28/2017)... , March 28, 2017 ... Pharmaceutical Marketing Strategies: Digital as a Key Component ... the changing pharmaceutical marketing landscape in the digital ... new technologies to provide medical advancements, it has ... marketing efforts, mostly relying on traditional channels and ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... in state legislatures and Congress to protect parental rights and civil liberties, and ... safety in America. , The demonstration coincides with a press conference taking place ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of the ... Wentz talked about journey and research recently on a blog and discussed some major ... solution to deal with thyroid disease. , Dr. Wentz completed her graduation from ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, ... the launch of a free, public-facing tool for analyzing the costs of various ... to provide comparative information to patients, providers, insurers and pharmaceutical companies about the ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control ... , The program, developed in association with efforts by the American College of ...
Breaking Medicine News(10 mins):